Insurance Denied Crohn's Disease Treatment? How to Appeal Biologic Denials for Humira, Stelara, and Entyvio

Crohn's disease is a chronic inflammatory bowel disease (IBD) affecting approximately 780,000 Americans. Moderate-to-severe Crohn's often requires biologic therapy — including adalimumab (Humira), ustekinumab (Stelara), vedolizumab (Entyvio), infliximab (Remicade), or risankizumab (Skyrizi) — to achieve and maintain remission. These medications are FDA-approved, supported by clinical guidelines, and in many cases medically necessary to prevent serious complications including bowel obstruction, fistulas, and the need for surgery. Insurers deny them at alarming rates, typically through step therapy requirements that force patients to fail less effective treatments first.

Why Insurers Deny Crohn's Biologics

• Step therapy mandates: Insurers require failure of conventional immunomodulators (azathioprine, 6-mercaptopurine, methotrexate) before approving biologic therapy, even when AGA guidelines support early biologic use for moderate-to-severe disease
• "Not medically necessary" despite FDA approval: Insurers argue the patient's disease severity doesn't meet their internal criteria, overriding the treating gastroenterologist's clinical assessment
• Preferred biologic substitution: The insurer approves a different biologic than prescribed, ignoring meaningful differences in mechanism of action, route of administration, and individual patient response
• Biosimilar substitution without physician consent: Insurers substitute a biosimilar for the reference biologic mid-treatment, risking immunogenicity reactions in patients who have been stable on the original product
• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denied for renewal: A patient who was previously approved and has achieved remission may be denied at renewal if they don't re-meet renewed criteria, despite the fact that they are in remission because of the medication

Common denial codes: CO-50 (not medically necessary), CO-97 (procedure bundled), B15 (authorization not obtained), CO-4 (modifier inconsistency).

How to Appeal a Crohn's Biologic Denial

Step 1: Document Disease Severity with Objective Measures

Your gastroenterologist's notes must include objective severity documentation: ICD-10 K50.x (Crohn's disease, various sites); Harvey-Bradshaw Index (HBI) or Crohn's Disease Activity Index (CDAI) score; Simple Endoscopic Score for Crohn's Disease (SES-CD) from colonoscopy; CRP, fecal calprotectin, or other inflammatory markers; and radiographic findings from CT or MRI enterography. An appeal without objective severity measures is easily dismissed on medical necessity grounds.

Step 2: Cite AGA and ACG Clinical Guidelines Directly

The American Gastroenterological Association (AGA) Clinical Guidelines for Crohn's Disease (2021) recommend anti-TNF therapy (adalimumab, infliximab) or ustekinumab as first-line biologic therapy for moderate-to-severe Crohn's disease. The AGA specifically notes that early biologic use may alter disease course more effectively than step-up therapy in high-risk patients. The American College of Gastroenterology (ACG) Management of Crohn's Disease in Adults guideline (2018, updated 2021) similarly supports biologic therapy in moderate-to-severe disease and does not mandate prior immunomodulator failure in all cases. These guidelines directly contradict step therapy mandates that require prior immunomodulator failure.

Step 3: Invoke State Step Therapy Reform Law

Over 30 states have step therapy protection laws requiring insurers to grant exceptions when: the required drug is contraindicated; the patient previously tried and failed it; the required drug has a reasonable likelihood of causing an adverse reaction; or the patient is stable on the requested medication and switching would cause clinical harm. Common Crohn's exception arguments include: history of hepatotoxicity or bone marrow suppression on azathioprine or 6-MP; prior failure of an anti-TNF agent (supporting escalation to Stelara or Entyvio with different mechanisms); or high-risk disease features (penetrating disease, perianal disease, prior bowel surgery) where rapid disease control is necessary.

Step 4: Document FDA-Approved Indications for the Prescribed Drug

Include FDA approval documentation for the prescribed biologic: Humira (adalimumab) FDA-approved for moderate-to-severe Crohn's since 2007; Stelara (ustekinumab) since 2016; Entyvio (vedolizumab) since 2014; Skyrizi (risankizumab) since 2022. If the insurer's coverage policy hasn't been updated to reflect newer indications (particularly for risankizumab), document this discrepancy explicitly.

Step 5: Request Peer-to-Peer Review

Ask for a direct conversation between your gastroenterologist and the insurer's medical reviewer. Peer-to-peer calls are often the fastest path to authorization, allowing your physician to articulate the clinical complexity of your case — fistula involvement, perianal disease, prior surgical history — that a paper review may not capture.

Step 6: File for External Independent Review: Complete Guide" class="auto-link">External Review if Internal Appeal Fails

Gastroenterology has well-established, consensus-based guidelines. External reviewers with GI expertise frequently overturn biologic denials that conflict with AGA or ACG standards. Request a reviewer with gastroenterology or IBD expertise.

What to Include in Your Appeal

• Gastroenterologist notes with HBI/CDAI scores and endoscopic findings: Objective disease severity documentation
• Lab results: CRP, fecal calprotectin, CBC, liver function tests showing disease activity and prior medication tolerance
• Prior medication history with outcomes: Specific drugs, doses, duration, and documented outcomes or adverse effects for all prior therapies
• AGA and ACG guideline citations: Specific sections supporting early biologic use in high-risk or moderate-to-severe disease
• FDA approval summary: For the specific biologic being requested

Fight Back With ClaimBack

Crohn's disease is a serious, lifelong condition where delays caused by insurance denials can lead to complications, hospitalizations, and surgery that proper biologic therapy could have prevented. When AGA and ACG guidelines support biologic use and your physician has documented clinical necessity, these appeals succeed. ClaimBack helps you organize the evidence and appeal quickly and effectively. ClaimBack generates a professional appeal letter in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal